Combined effects of IL-8 and CXCR2gene polymorphisms on breast cancer susceptibility and aggressiveness

BMC Cancer

Research Article

Kaouther Snoussi¹  Wijden Mahfoudh¹  Lotfi Chouchane²  Noureddine Bouaouina³  Meriem Fekih⁴  Hedi Khairi⁴  Ahmed N Helal⁵ 

[1] Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Université de Monastir, 5019, Monastir, Tunisia;Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Université de Monastir, 5019, Monastir, Tunisia;Department of Genetic Medicine, Weill Cornell Medical College in Qatar, P.O.Box 24144, Doha, Qatar;Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Université de Monastir, 5019, Monastir, Tunisia;Départment de Cancérologie Radiothérapie, CHU Farhat Hached, 4000, Sousse, Tunisia;Service d'Obstétrique et des maladies féminines, Centre Hospitalo-Universitaire-Farhat-Hached de Sousse, 4000, Sousse, Tunisia;Unité Génome, Diagnostic Immunitaire et Valorisation, Institut Supérieur de Biotechnologie de Monastir, Université de Monastir, 5000, Monastir, Tunisia;

关键词: Breast Cancer;    Breast Carcinoma;    Benign Breast Disease;    Human Microvascular Endothelial Cell;    Oral Contraceptive Usage;   

DOI  :  10.1186/1471-2407-10-283

 received in 2009-10-14, accepted in 2010-06-12,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundInterleukin-8 (IL-8/CXCL-8) is a prototype of the ELR+CXC chemokines that play an important role in the promotion and progression of many human cancers including breast cancer. We have recently showed the implication of polymorphism (-251) T/A of IL-8 gene in the susceptibility and prognosis of breast carcinoma. IL-8 acts through its CXCR1 and CXCR2 receptors. CXCR2, expressed on the endothelial cells, is the receptor involved in mediating the angiogenic effects of ELR+CXC chemokines and in particular IL-8.In the current study, we investigated the susceptibility and prognostic implications of the genetic variation in CXCR2 in breast carcinoma. We also confirmed the implication of IL-8 (-251) T/A polymorphism in a larger cohort. Finally, we combined the IL-8 and CXCR2 variant alleles and analyzed their effects in breast cancer risk and prognosis.MethodsWe used the allele-specific polymerase chain reaction to characterize the variation of IL-8 and CXCR2 for 409 unrelated Tunisian patients with breast carcinoma and 301 healthy control subjects. To estimate the relative risks, Odds ratios and 95% confidence intervals were calculated using unconditional logistic regression after adjusting for the known risk factors for breast cancer. Associations of the genetic marker with the rates of breast carcinoma-specific overall survival and disease-free survival were assessed using univariate and multivariate analyses.ResultsA highly significant association was found between the homozygous CXCR2 (+ 1208) TT genotype (adjusted OR = 2.89; P = 0.008) and breast carcinoma. A significantly increased risk of breast carcinoma was associated with IL-8 (-251) A allele (adjusted OR = 1.86; P = 0.001). The presence of two higher risk genotypes (the TA and TT in IL-8, and the TT in CXCR2) significantly increased the risk of developing breast carcinoma (adjusted OR = 4.15; P = 0.0004).The CXCR2 (+ 1208) T allele manifested a significant association with an aggressive phenotype of breast carcinoma as defined by a large tumor size, a high histological grade, and auxiliary's lymph node metastasis. A significant association between the IL-8 (-251) A allele and the aggressive form of breast carcinoma was also found.Moreover, the presence of the IL-8 (-251) A and/or the CXCR2 (+ 1208) T allele showed a significant association with a decreased overall survival and disease-free survival in breast carcinoma patients.ConclusionOur results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.

【 授权许可】

CC BY   
© Snoussi et al; licensee BioMed Central Ltd. 2010